- Piper Sandler Companies (PIPR, Financial) expands its biotechnology equity research team.
- Kelsey Goodwin joins as a director and senior research analyst focusing on oncology.
- Goodwin brings extensive expertise from previous roles at Guggenheim and in pharmaceutical strategy consulting.
Piper Sandler Companies (PIPR), a leading investment bank, has announced the appointment of Kelsey Goodwin as a director and senior research analyst for its biotechnology equity research team. Goodwin will be based in the Boston office and will cover oncology.
"We are excited to welcome Kelsey to the Piper Sandler platform. She brings a deep understanding and passion for our industry and builds strong relationships to serve clients. We are deeply committed to the biotechnology sector and Kelsey’s addition will only strengthen our industry-leading biopharma research practice that is collaborative and energized to provide insights for our clients," said Michael Cox, co-head of global equities at Piper Sandler.
Goodwin previously spent seven years at Guggenheim, where she specialized in oncology therapeutics. Her background also includes three years in pharmaceutical strategy consulting. She holds a bachelor's degree in biology from Bowdoin College.
Expressing her enthusiasm for her new role, Goodwin stated, "I am beyond thrilled to join Piper Sandler, a firm with a longstanding reputation not only for its excellence and high-quality research, but also for its people. I look forward to joining the exceptionally talented, hard-working, and collaborative team, and to contributing to the continued success of the firm and its clients."
Piper Sandler Companies (PIPR, Financial) provides securities brokerage and investment banking services across the United States, Europe, and Hong Kong, and is known for its commitment to client partnerships in the financial sector.
